Eric Nuermberger, MD is Professor of Medicine and International Health at Johns Hopkins University, where he completed a residency in Internal Medicine and a fellowship in Infectious Diseases. Since 2001, he has been primarily engaged in pre-clinical TB drug development research using in vitro and murine models. This work has informed the clinical development of moxifloxacin, rifapentine, bedaquiline, pretomanid, clofazimine and several oxazolidinones for TB and the pre-clinical development of numerous other compounds. This work has been funded by the National Institutes of Health, the Bill and Melinda Gates Foundation, the Global Alliance for TB Drug Development, the Food and Drug Administration, and a number of pharmaceutical sponsors. Dr. Nuermberger serves as a member of the AIDS Clinical Trial Group’s TB Transformative Science Group and the Core Science Group of the TB Trials Consortium, Co-Chair of the Preclinical and Clinical Sciences Work Group of CPTR, and Associate Editor of Antimicrobial Agents and Chemotherapy.
